The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...

AstraZeneca has punted a pair of early-phase prostate cancer progra | AstraZeneca has punted a pair of early-phase prostate ...

With the U.S. patent on the immunology megablockbuster Dupixent set to expire in 2031, time is running out for Sanofi to find ...

Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...

BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...

Bristol Myers Squibb has scrapped a phase 1 program it licensed from Prothena for $80 million. | Bristol Myers Squibb has ...

Flagship Pioneering unveiled Etcelera today, a new AI-powered biotech emerging from stealth that aims to predict how ...

Audax sees the propensity for IL-12 drugs to bind receptors on peripheral immune cells as a driver of the dosing and toxicity ...

To many, 2026 is the year the biotech industry came back to life. The XBI—an exchange-traded fund that tracks the U.S. | ...

GSK’s global restructuring plan is likely to see “some limited impact” on roles in the Big Pharma’s home turf of the U.K., ...

Scientists have known for a while that Angelman syndrome is caused by the loss of a specific gene, but they didn't understand ...

Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper ...